Biosimilars at Kaiser Permanente

Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic drugs in the United States.

Read the paper: Biosimilars at Kaiser Permanente

Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic drugs in the United States.

Read the paper: Biosimilars at Kaiser Permanente

Related articles

Restoring Provider Confidence In FDA-Approved Drugs

The Kaiser Permanente Institute for Health Policy's experts Samantha Dupont, Krysten Joyce and Murray Ross join Kaiser Permanente's Senior Vice President of Government Relations, Tony Barrueta, to  share their insights on the policy prescriptions needed to ensure prescribed drugs are…

Evolving nature of evidence required by FDA to approve new drugs

This brief, based on systematic reviews conducted in collaboration with the Program on Therapeutics, And Law (PORTAL), provides background on the evidence required by the Food and Drug Administration (FDA) to support drug approval. It highlights changes in the amount…

Health care workforce needs and Kaiser Permanente’s approach

download as a PDF The challenge Health care workforce needs To meet the health care needs of the future, the nation needs more health care workers and a diverse workforce with the right experiences, skills, cultural diversity, and linguistic capabilities…